Insider Selling: ASP Isotopes (NASDAQ:ASPI) CEO Sells 22,500 Shares of Stock

Key Points

• CEO Robert Ainscow of ASP Isotopes sold 22,500 shares at an average price of $13.60, totaling $306,000, reducing his shareholding by 1.35%.
• The company reported a loss of ($1.03) EPS for the last quarter, missing analysts' expectations, with revenue of $1.20 million against estimates of $1.60 million.
• A SP Isotopes stock is rated as "Hold" with a consensus target price of $11.00, as confirmed by various research analysts.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Robert Ainscow sold 22,500 shares of the stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $13.60, for a total transaction of $306,000.00. Following the transaction, the chief executive officer owned 1,647,193 shares of the company's stock, valued at $22,401,824.80. This represents a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Ainscow also recently made the following trade(s):

• On Monday, September 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The stock was sold at an average price of $8.53, for a total transaction of $71,976.14.

ASP Isotopes Price Performance

Shares of ASP Isotopes stock traded down $1.57 on Thursday, reaching $11.05. The stock had a trading volume of 15,453,034 shares, compared to its average volume of 9,699,471. ASP Isotopes Inc. has a 1 year low of $3.64 and a 1 year high of $14.49. The company has a market cap of $1.02 billion, a P/E ratio of -18.11 and a beta of 3.29. The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53. The business's 50 day moving average is $9.75 and its two-hundred day moving average is $8.12.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). The firm had revenue of $1.20 million during the quarter, compared to analysts' expectations of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. As a group, research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ASP Isotopes in a research note on Wednesday, October 8th. Canaccord Genuity Group reissued a "buy" rating and set a $11.00 price target on shares of ASP Isotopes in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $11.00.

Hedge Funds Weigh In On ASP Isotopes

Large investors have recently modified their holdings of the stock. Exchange Traded Concepts LLC purchased a new position in shares of ASP Isotopes in the 2nd quarter worth about $9,593,000. Harbour Capital Advisors LLC purchased a new position in shares of ASP Isotopes in the 2nd quarter worth about $232,000. Philadelphia Financial Management of San Francisco LLC raised its position in shares of ASP Isotopes by 11.2% in the 1st quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company's stock worth $16,453,000 after purchasing an additional 354,517 shares during the last quarter. PFG Investments LLC purchased a new position in shares of ASP Isotopes in the 1st quarter worth about $94,000. Finally, AWM Investment Company Inc. raised its position in shares of ASP Isotopes by 6.2% in the 1st quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company's stock worth $21,157,000 after purchasing an additional 265,000 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.